Sign In

Communications of the ACM

ACM TechNews

Novartis, Microsoft Join Forces to Develop Drugs Using AI


View as: Print Mobile App Share: Send by email Share on reddit Share on StumbleUpon Share on Hacker News Share on Tweeter Share on Facebook
The Microsoft and Novartis logos.

Novartis and Microsoft plan to use artificial intelligence to develop new drugs faster, and with greater precision.

Credit: FT.com

Novartis and Microsoft have agreed to a five-year partnership to use artificial intelligence (AI) to develop new drugs faster, and with greater precision.

Novartis CEO Vas Narasimhan said AI's potential for personalized medicine is particularly promising, as it will help classify subgroups of patients that new drugs will most likely benefit, using clinical and preclinical datasets.

Narasimhan added that these datasets were consolidated from Novartis' internal information, surmounting integration obstacles.

The ultimate goal of the alliance is to use AI to fuel research, development, manufacturing, finance, sales, marketing, and acquisitions.

The partners initially will target their application of AI to personalized treatments for macular degeneration, cell and gene therapy, and drug design.

From Financial Times
View Full Article - May Require Paid Subscription

 

Abstracts Copyright © 2019 SmithBucklin, Washington, DC, USA


 

No entries found

Sign In for Full Access
» Forgot Password? » Create an ACM Web Account